The impact of neutrophil-to-lymphocyte ratio after two courses of pembrolizumab for oncological outcomes in patients with metastatic urothelial carcinoma

HIGHLIGHTS

  • who: Risa Tomioka-Inagawa et al. from the Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan have published the Article: The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma, in the Journal: Biomedicines 2022, 1609 of 13/05/2022
  • what: The authors focused on the therapeutic effect of pembrolizumab for metastatic urothelial carcinoma (mUC) and evaluated predictive factors for improving clinical outcomes.
  • how: The authors conducted a retrospective multicenter cohort study of patients with mUC who received pembrolizumab . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?